Transgene Biotek Limited share price
BSE: TRABI
Key numbers
- Market cap
- ₹ 19.7 Cr
- Current price
- ₹ 2.60
- 52-week high / low
- ₹ 4 / 2
- Stock P/E
- -
- Book value
- ₹ 1.1
- Dividend yield
- 0.00%
- ROCE
- -2.4%
- ROE
- -17.9%
- Debt to equity
- 2.05
- Sales growth (3 yrs)
- 51.8%
- Profit growth (3 yrs)
- -
- 1-year return
- -32.3%
About Transgene Biotek Limited
Transgene Biotek Limited, a biotechnology company, provides research and development services for bulk drugs in India. It offers a portfolio of oncology drugs, oral drug delivery, and biogenerics. The company provides TrabiDHA for use in health food, baby food/formula, health supplement, and chicken and animal feed markets; Tacrolimus, a drug that suppresses the immune system and is used to prevent rejection of transplanted organs; and Orlistat (tetrahydrolipstatin), a lipase inhibitor that blocks about one-third of intestinal fat absorption. The company was incorporated in 1990 and is based in Sangareddy, India.
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 |
| Operating profit | -0 | -0 | -0 | -0 | -0 |
| Net profit | -0 | -0 | -0 | -0 | -0 |
| EPS (₹) | -0.06 | -0.05 | -0.05 | -0.06 | -0.05 |
Peers in Biotechnology
Data for information only, not investment advice. Prices end of day.